---
title: "Zhejiang East-Asia Pharmaceutical Co., Ltd. (605177.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/605177.SH.md"
symbol: "605177.SH"
name: "Zhejiang East-Asia Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T20:45:35.640Z"
locales:
  - [en](https://longbridge.com/en/quote/605177.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/605177.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/605177.SH.md)
---

# Zhejiang East-Asia Pharmaceutical Co., Ltd. (605177.SH)

## Company Overview

Zhejiang East Asia Pharmaceutical Co., Ltd. produces and sells pharmaceutical chemicals, tablets, granules, intermediates, and capsules. It offers quinolones synthetic antibacterial agents, antifungal products, gastrointestinal medications, semi-synthetic cephalosporin antibiotics, carbapenem antibiotics, antiviral agents, central nervous system medications, respiratory drugs, antiallergic agents, antineoplastic agents and tumor adjuvant drugs, and other products. The company provides products in the fields of cardiovascular, anti-aging dementia, digestive system, diabetic neuropathy, and anti-pathogenic microorganisms.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.eapharm.cn](https://www.eapharm.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: D (0.61)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 207 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -2.19% |  |
| Net Profit YoY | 15.91% |  |
| P/B Ratio | 1.54 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2559366805.47 |  |
| Revenue | 1015637281.07 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -6.07% | D |
| Profit Margin | -10.92% | D |
| Gross Margin | 21.33% | D |
| Revenue YoY | -2.19% | D |
| Net Profit YoY | 15.91% | C |
| Total Assets YoY | -7.12% | E |
| Net Assets YoY | -5.17% | D |
| Cash Flow Margin | 92.34% | C |
| OCF YoY | -2.19% | D |
| Turnover | 0.30 | D |
| Gearing Ratio | 45.20% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zhejiang East-Asia Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-2.19%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "15.91%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.54",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2559366805.47",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1015637281.07",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-6.07%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-10.92%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "21.33%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "-2.19%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "15.91%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-7.12%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-5.17%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "92.34%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-2.19%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.30",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "45.20%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -23.09 | 190/215 | - | - | - |
| PB | 1.54 | 47/215 | 1.44 | 1.35 | 1.25 |
| PS (TTM) | 2.52 | 55/215 | 2.91 | 2.46 | 2.26 |
| Dividend Yield | 0.00% | - | 1.81% | 1.76% | 1.72% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/605177.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/605177.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/605177.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/605177.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**